Recent developments for Synlogic include financial results reporting, government contract awards, and analyst coverage updates.

• Synlogic reported a net loss for Q4 2023 but topped revenue estimates for that quarter [N1].
• The company secured a $1 million subcontract under the Air Force Research Lab in December 2023 [N3].
• Multiple analyst firms, including HC Wainwright & Co. and Alliance Global Partners, have reiterated or initiated buy recommendations for Synlogic during 2023 [N4][N6].
• Synlogic reported a net loss and missed revenue estimates in Q2 2023 [N7].
• The company was noted among pre-market movers in September 2023 [N5].

Synlogic has secured government contracts and maintains a strong liquidity position, which supports ongoing research and development activities. The company benefits from experienced leadership and board members with deep industry knowledge. Multiple analyst buy recommendations suggest confidence in the company's strategic direction and potential value creation through partnerships or corporate transactions.

Synlogic reported no revenue and a net loss for the fiscal year ended 2025, indicating ongoing operational challenges. The company operates with a minimal workforce and has been delisted from Nasdaq, trading instead on the OTC Marketplace, which may limit liquidity and investor access. The biotechnology sector's inherent risks, including regulatory hurdles and development uncertainties, present ongoing challenges for Synlogic's business model and financial sustainability.

Synlogic's moat is primarily based on its specialized biotechnology expertise and strategic partnerships, including government contracts such as the subcontract with the Air Force Research Lab. The company's governance structure and experienced board provide oversight and strategic direction. However, the company currently reports no revenue and operates with limited personnel, indicating a focus on development and strategic positioning rather than established commercial operations.

• Financial Performance Risk: The company reported no revenue and a net loss of $1.005 million for fiscal 2025, indicating ongoing operational losses and reliance on external funding or strategic transactions.
• Market Listing and Liquidity Risk: Delisting from Nasdaq and trading on the OTC Marketplace may reduce stock liquidity and investor visibility, potentially impacting capital raising and shareholder value.
• Operational Scale Risk: With only one full-time employee as of March 31, 2026, the company operates at a minimal scale, which may limit its ability to execute on development and commercialization plans independently.
• Biotechnology Development Risk: As a biotechnology company, Synlogic faces risks related to regulatory approvals, clinical trial outcomes, and competitive pressures inherent in the sector.

• Synlogic, Inc. is a Delaware corporation with its principal executive offices in Winchester, Massachusetts.
• As of March 31, 2026, Synlogic had 11,698,919 shares of common stock outstanding.
• The company is classified as a non-accelerated filer and a smaller reporting company.
• Synlogic's Board of Directors consists of four members with extensive experience in life sciences and finance, including Chairman Peter Barrett, Ph.D., and directors James Flynn, Edward Mathers, and Richard P. Shea, all deemed independent.
• The company has an Audit Committee and a Compensation Committee with defined roles and responsibilities.
• Synlogic's business operations continue despite delisting from Nasdaq and trading on the OTC Marketplace.
• The company had cash and cash equivalents of $14.7 million and current assets of $15.4 million as of December 31, 2025, with current liabilities of $3.58 million, resulting in a current ratio of 4.3 and a cash ratio of 31.61.
• Synlogic reported zero revenue and a net loss of $1.005 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$0.08 per share.
• The company secured a $1 million subcontract under the Air Force Research Lab as of December 2023.
• Synlogic has been the subject of multiple analyst buy recommendations and reiterated buy ratings from firms such as HC Wainwright & Co. and Alliance Global Partners.
• Recent quarterly reports indicate losses with some quarters missing revenue estimates and others topping revenue estimates.
• The company has ongoing equity incentive plans and indemnification agreements with directors and officers.
• Synlogic's governance includes corporate governance guidelines, a Code of Conduct, and risk oversight by the Board and its committees.
• The company had one full-time employee as of March 31, 2026, primarily engaged in strategic transaction assessment.
• Synlogic's common stock was last quoted at $0.61 as of March 15, 2026.
• The company has a history of strategic evaluations including potential mergers or sales as part of its business strategy.